ValiRx Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

CEO

ValiRx CEO'su yok ya da onlar hakkında elimizde veri yok.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Desler	CFO, Company Secretary & Executive Director	18.5yrs	UK£69.11k	0.15% € 3.9k
Catherine Tralau-Stewart	Executive Director	1.8yrs	Veri yok	Veri yok
Jeremy Anthony Randall	Member of Commercial Advisory Board	no data	Veri yok	Veri yok
Paul Taylor	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Christophe Chassagnole	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Wilson Caparrós-Wanderley	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Mark Eccleston	Member of Scientific & Commercial Advisory Board	no data	Veri yok	Veri yok
Martin Gouldstone	Independent Non-Executive Chairman	less than a year	Veri yok	Veri yok
Ray Horn	Board observer	less than a year	Veri yok	Veri yok
Adrian Courcey	Independent Non-Executive Director	less than a year	Veri yok	0.66% € 17.6k
Gareth Griffiths	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

0.7yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: EAJF 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.7 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

ValiRx Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

ValiRx plc Announces Resignation of Martin Lampshire as A Non-Executive Director

Valirx plc Announces Change in Chief Executive Officer

ValiRx plc Announces Board Changes

Valirx plc Announces Resignation of Kevin Cox as Chairman and Director

ValiRx plc, Annual General Meeting, Jun 20, 2024

Recent updates

Less than half of directors are independent

ValiRx plc Announces Resignation of Martin Lampshire as A Non-Executive Director

Valirx plc Announces Change in Chief Executive Officer

ValiRx plc Announces Board Changes

Valirx plc Announces Resignation of Kevin Cox as Chairman and Director

ValiRx plc, Annual General Meeting, Jun 20, 2024

Valirx plc Announces Directorate Changes

Less than half of directors are independent

New minor risk - Financial data availability

Valirx plc Intends to Appoint Martin Gouldstone as Non-Executive Director

ValiRx plc Announces Resignation of Stella Panu as A Non-Executive Director, Effective from 15 April 2024

ValiRx plc has completed a Follow-on Equity Offering in the amount of £0.192244 million.

ValiRx plc has completed a Follow-on Equity Offering in the amount of £1.5795 million.

ValiRx plc, Annual General Meeting, Jan 04, 2024

New major risk - Market cap size

New major risk - Share price stability

ValiRx plc (AIM:VAL) acquired scientific assets of Imagen Therapeutics Limited from Imagen Therapeutics Ltd for £0.17 million.

ValiRx plc (AIM:VAL) acquired scientific assets of Imagen Therapeutics Limited from Imagen Therapeutics Ltd for £0.17 million.

New major risk - Market cap size

ValiRx plc, Annual General Meeting, Jun 28, 2023

ValiRx plc to Report Q4, 2022 Results on Jun 05, 2023

ValiRx plc Appoints Cathy Tralau-Stewart as Chief Scientific Officer

Less than half of directors are independent

ValiRx plc Appoints Stella Panu as Non-Executive Director

Less than half of directors are independent

ValiRx Plc Announces Appointment of Dr. Catherine Tralau Interim Chief Scientific Officer

Kevin Alexander Ceased to Be Director of ValiRx

ValiRx plc, Annual General Meeting, Jun 30, 2022

Non-Executive Director recently bought €115k worth of stock

London, Uk - Valirx plc Announces That It Has Entered into A New Agreement with Physiomics Plc

Valirx plc Receives the Full Dataset to Be Used for the Clinical Study Report from the Phase 1/2 Clinical Trial of Its Lead Asset, VAL201

ValiRx plc Reports Headline Results from the Recently Completed Phase 1/2 Clinical Trial of its Lead Asset VAL201

New 90-day high: €0.38

New 90-day high - €0.28

New 90-day high - €0.22

CEO

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş